permanenthirecareers.com

Alec Difrawi aka Alec Defrawy aka Ayman A. El-Difrawi and his affiliated companies such as Softrock, Inc., Softrockcareers.com, Career Network, JobNab, Softrock.org OMG Talent, MonkeyJar, Internet Solutions Corporation owns thousand of domains that he uses to market Career Education or Higher Education to US Veterans and other unsuspecting job seekers.

From what we’ve researched over the years, Mr. Difrawi crave for notoriety. He portrays himself larger than life and sustain his operations based on his family wealth.
He advertises Administrative Assistants, Medical Assistant, Dental Assistants, Skilled Labor Careers, Criminal Justice Jobs, Homeland Security Jobs, Court Career Jobs, Warehouse Jobs, Accounting Jobs, Criminal Justice Jobs, Jobs For Veterans,Supervisor jobs
medical Careers Online,Maintenance Worker, Medical and Fitness Trainer, Medical Billing and Coding to name a few paying thousands more than the average pay rate.

In short, Alec Difrawi is a Career Education Sales Marketer, a Model Talent Search marketer and a business franchises marketer. These are his core online businesses along with his family assets of construction and real estates holdings associated with Expand Incorporated a minority contractor for the Department of Defense.

Mr. Difrawi his related companies and websites must tell job seekers on each page of each website what it is he advertising. That the job they are applying for is an opportunity for career college higher education training.



Advertisements

FDA Warning Letter – NorthWestPharmacy.com

Public Health Service
Food and Drug Administration
Silver Spring, MD  20993-0002

TO: CustomerService@NorthWestPharmacy.com
FROM:United States Food and Drug Administration
Center for Drug Evaluation and Research
Office of Compliance
Office of Drug Security, Integrity and Recalls
Division of Supply Chain Integrity
RE:    Internet Marketing of an Unapproved and Misbranded Drug
DATE:     May 24, 2012

WARNING LETTER

The United States Food and Drug Administration (FDA) reviewed your website, www.NorthWestPharmacy.com, on January 4, 2012 and has determined that your website offers products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the website offers an unapproved and misbranded new drug for sale in violation of sections 502(f) and 505(a) of the FD&C Act [21 U.S.C. §§ 352(f) and 355(a)], which are prohibited acts under sections 301(a) and 301(d) of the FD&C Act [21 U.S.C. §§ 331(a) and 331(d)], respectively. We request that you immediately cease marketing violative drug products to United States consumers.

Unapproved New Drug

Alitretinoin, trade name, Toctino, is offered for sale on your website “to treat severe long-term eczema that affects the hands … for patients who have not found success using other corticosteroid treatments.” Based on this claim, Toctino appears to be a drug within the meaning of section 201(g) of the FD&C Act [21 U.S.C. §321(g)] because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or it is intended to affect the structure or function of the body. Moreover, Toctino appears to be a new drug within the meaning of section 201 (p) of the FD&C Act [21 U.S.C. §321(p)] because it is not generally recognized as safe and effective for its labeled use. Although Toctino is approved in Canada, no approved application pursuant to section 505 of the FD&C Act [21 U.S.C. §355] is in effect for this product. Accordingly, its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act [21 U.S.C. §355(a)] and is prohibited under section 301(d) of the FD&C Act [21 U.S.C. §331(d)].

Misbranded Drug

Alitretinoin is a retinoid that is potentially dangerous when orally administered due to its teratogenicity. Because of this potential toxicity, its Canadian labeling states that it should be prescribed only by physicians knowledgeable in the use of systemic retinoids and who understand the risks of teratogenicity in females of childbearing potential. In addition, these females are required to have pregnancy tests before, at regular intervals during, and after discontinuation of alitretinoin therapy to exclude pregnancy. Because Toctino is unapproved in the United States, these safety controls are bypassed when alitretinoin is purchased over the Internet by customers in the United States without consultation with and a valid prescription from a physician. This places American patients who use the drug at risk for adverse effects. Thus, Toctino offered for sale on your website is misbranded within the meaning of section 502(f)(1) of the FD&C Act [21 U.S.C. §321(f)(1)] in that the labeling for Toctino fails to bear adequate directions for use. The introduction or delivery for introduction into interstate commerce of a misbranded drug product is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. §331(a)].

FDA is taking action against your firm because of the inherent risk in buying unapproved and misbranded new drugs. Unapproved new drugs may not have the same assurance of safety, efficacy, and quality as drugs subject to FDA oversight, and such drugs have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. FDA- regulated drugs offer protections that include rigorous scientific standards for new drug approval, labeling review for accuracy and completeness, and manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities. In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public may not be safe and effective.

This letter is not intended to identify all of the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products marketed by your firm are in compliance with FD&C Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in FDA regulatory action, including but not limited to, seizure or injunction, without further notice.

Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to DrugSupplyChainintegrity@fda.hhs.gov. Please direct any inquiries concerning this letter to Leigh Verbois, Acting Deputy Director for the Division of Supply Chain Integrity at the above address.

Sincerely,

/s/

Thomas Christl, Office Director (Acting)
Office of Drug Security, Integrity and Recalls
Office of Compliance

FDA Warning Letter – Best Price Rx

TO:          Best Price Rx
#501-2906 West Broadway
Vancouver, BC, Canada V6K 208

FROM:     United States Food and Drug Administration
Center for Drug Evaluation and Research
Office of Compliance
Office of Drug Security, Integrity and Recalls
Division of Supply Chain Integrity

RE:           Internet Marketing of an Unapproved and Misbranded Drug

DATE:       May 24, 2012

WARNING LETTER

The United States Food and Drug Administration (FDA) reviewed your website, http://www.bestpricerx.com, on January 31, 2012 and has determined that your website offers products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the website offers an unapproved and misbranded new drug for sale in violation of sections 502(f) and 505(a) of the FD&C Act [21 U.S.C. §§ 352(f) and 355(a)], which are prohibited acts under sections 301(a) and 301(d) of the FD&C Act [21 U.S.C. §§ 331(a) and 331(d)], respectively. We request that you immediately cease marketing violative drug products to United States consumers.

Unapproved New Drug

Alitretinoin, trade name, Toctino, which you offer for sale on your website is a drug within the meaning of section 201(g) of the FD&C Act [21 U.S.C. §321(g)] because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or it is intended to affect the structure or function of the body. Moreover, Toctino appears to be a new drug within the meaning of section 201(p) of the FD&C Act [21 U.S.C. §321(p)] because it is not generally recognized as safe and effective for its labeled use. Although Toctino is approved in Canada, no approved application pursuant to section 505 of the FD&C Act [21 U.S.C. §355) is in effect for this product. Accordingly, its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act [21 U.S.C. §355(a)] and is prohibited under section 301(d) of the FD&C Act [21 U.S.C. §331(d)].

Misbranded Drug

Alitretinoin is a retinoid that is potentially dangerous when orally administered due to its teratogenicity. Because of this potential toxicity, its Canadian labeling states that it should be prescribed only by physicians knowledgeable in the use of systemic retinoids and who understand the risks of teratogenicity in females of childbearing potential. In addition, these females are required to have pregnancy tests before, at regular intervals during, and after discontinuation of alitretinoin therapy to exclude pregnancy. Because Toctino is unapproved in the United States, these safety controls are bypassed when alitretinoin is purchased over the Internet by customers in the United States without consultation with and a valid prescription from a physician. This places American patients who use the drug at risk for adverse effects. Thus, Toctino offered for sale on your website is misbranded within the meaning of section 502(f)(1) of the FD&C Act [21 U.S.C. §321(f)(1)] in that the labeling for Toctino fails to bear adequate directions for use. The introduction or delivery for introduction into interstate commerce of a misbranded drug product is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. §331(a)].

FDA is taking action against your firm because of the inherent risk in buying unapproved and misbranded new drugs. Unapproved new drugs may not have the same assurance of safety, efficacy, and quality as drugs subject to FDA oversight, and such drugs have been found to be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. FDA-regulated drugs offer protections that include rigorous scientific standards for new drug approval, labeling review for accuracy and completeness, and manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities. In addition, pharmacies and wholesalers who sell or distribute prescription drugs in the U.S. are licensed by the states. Unapproved new drugs delivered to the American public may not be safe and effective.

This letter is not intended to identify all of the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products marketed by your firm are in compliance with FD&C Act and its implementing regulations. You should take prompt action to correct the violations noted above. Failure to correct these violations promptly may result in FDA regulatory action, including but not limited to, seizure or injunction, without further notice.

Please notify this office in writing within 15 working days of receipt of this letter of any steps you have taken or will take to correct the noted violations and to prevent their recurrence. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response should be sent to DrugSupplyChainintegrity@fda.hhs.gov. Please direct any inquiries concerning this letter to Leigh Verbois, Acting Deputy Director for the Division of Supply Chain Integrity at the above address.

Sincerely,

/S/

Thomas Christl, Office Director (Acting)
Office of Drug Security, Integrity and Recalls
Office of Compliance

AppleOne Warns JobSeeker About Alec Difrawi Business Practices

Craigslist Ads Redirecting to the Web Site JobNab

We have had reports of ads posted to Craigslist claiming to be posted by or on behalf of AppleOne. When clicking through the apply link, you are redirected to a web site called JobNab. We are not affiliated with JobNab and have asked them to stop pretending to post on our behalf. We do not know what they will do with information you provide in their registration process, but urge caution. If you’d like to apply for any ApppleOne ad, you can start the online application process on our web site here: Apply to AppleOne Today.

AppleOne Will Not Ask You to Complete a Credit Report Prior to Your Interview

We have received reports of a new fraudulent advertiser who is using AppleOne’s name, as well as other major employment services, to lend credibility to their scams. Individuals who respond to their ads (on Craigslist and other sites) are directed to a third party site to complete a credit report prior to interview. Providing the information requested on that site may give these people everything they need to steal your identity, so we recommend caution. To protect yourself, please speak with somebody in one of our branch offices to be sure you are really dealing with AppleOne before providing any information that could be used to steal your identity.

AppleOne Does Not Charge Applicants To Find Work, and We Will Not Ask For Your Credit Card Number Before Working With You.

A new scam has been reported in which somebody calls claiming that they are a representative of AppleOne and that they have a few job opportunities. All they need to get started is a credit card number so they can send an enrollment packet. This person is NOT a representative of AppleOne and AppleOne will NOT ask you for a credit card in order to work with you. We never charge a fee to the applicant.

If you think you may have been a victim of this scam, please contact your local law enforcement agency and credit card companies with the details.

Customer Service Evaluator Check Cashing Fraud Alert

  • If you are in possession of a check sent by someone claiming to be from AppleOne then it’s a scam to defraud you.
  • AppleOne does not send unsolicited checks nor offer mystery shopper jobs.
  • If you are a job seeker AppleOne requires you apply online at AppleOne.Com or at a local branch office.

We have identified a scam in which criminals pretending to be from AppleOne are sending people checks and asking them to cash the checks and then return the money via Western Union. This is not a genuine AppleOne job. The people sending these checks are NOT affiliated with AppleOne in any way, and the checks are not real. If you attempt to cash the check it will bounce and you will have been defrauded of any funds you returned to the con artists via Western Union or any other means.

If you ever receive anything you’re unsure of that seems to come from AppleOne, feel free to contact your local branch office to check on the veracity of the materials. If you have received one of these fraudulent checks, please contact your local law enforcement agency with the details. You might also consider contacting the FTC.

Source:AppleONE

Appleone Warning.png

WhoIs – www.pageinsider.com

Content farming site for Google Adsense Purposes.

This site has been identified as a adsense troller and content farming. They do not provide any logical beneficial statistical information for the simple fact of attracting whoever have key in some search word mainly domain names.

google_pageinsider.png

Address lookup
canonical name pageinsider.com

aliases
addresses 23.21.103.74
Domain Whois record

Queried whois.internic.net with “dom pageinsider.com”…

Domain Name: PAGEINSIDER.COM
Registrar: TLDS, LLC DBA SRSPLUS
Whois Server: whois.srsplus.com
Referral URL: http://www.srsplus.com
Name Server: NS-1421.AWSDNS-49.ORG
Name Server: NS-1679.AWSDNS-17.CO.UK
Name Server: NS-312.AWSDNS-39.COM
Name Server: NS-629.AWSDNS-14.NET
Status: clientTransferProhibited
Updated Date: 16-feb-2012
Creation Date: 30-apr-2010
Expiration Date: 30-apr-2020

Last update of whois database: Thu, 28 Jun 2012 13:34:53 UTC
Queried whois.srsplus.com with “pageinsider.com”…

pageinsider.com

Registrant:
Page Insider pageInsider@activedots.com
PageInsider.com
2510 Channing Way #8
Berkeley, CA 94704
US
510-705-1470

Domain Name: pageinsider.com

Administrative, Technical, Billing Contact:
Page Insider pageInsider@activedots.com
PageInsider.com
2510 Channing Way #8
Berkeley, CA 94704
US
510-705-1470

Record created on Apr 30 2010.
Record expires on Apr 30 2020.
Domain servers:
ns-1421.awsdns-49.org
ns-629.awsdns-14.net
ns-1679.awsdns-17.co.uk
ns-312.awsdns-39.com

Domain Service Provider:
CompuCated Domains
domains@activedots.com

Network Whois record
Queried whois.arin.net with “n 23.21.103.74

NetRange: 23.20.0.0 – 23.23.255.255
CIDR: 23.20.0.0/14
OriginAS: AS16509
NetName: AMAZON-EC2-USEAST-10
NetHandle: NET-23-20-0-0-1
Parent: NET-23-0-0-0-0
NetType: Direct Assignment
Comment: The activity you have detected originates from a dynamic hosting environment.
Comment: For fastest response, please submit abuse reports at http://aws-portal.amazon.com/gp/aws/html-forms-controller/contactus/AWSAbuse
Comment: For more information regarding EC2 see:
Comment: http://ec2.amazonaws.com/
Comment: All reports MUST include:
Comment: * src IP
Comment: * dest IP (your IP)
Comment: * dest port
Comment: * Accurate date/timestamp and timezone of activity
Comment: * Intensity/frequency (short log extracts)
Comment: * Your contact details (phone and email) Without these we will be unable to identify the correct owner of the IP address at that point in time.
RegDate: 2011-09-19
Updated: 2012-03-02
Ref: http://whois.arin.net/rest/net/NET-23-20-0-0-1

OrgName: Amazon.com, Inc.
OrgId: AMAZO-4
Address: Amazon Web Services, Elastic Compute Cloud, EC2
Address: 1200 12th Avenue South
City: Seattle
StateProv: WA
PostalCode: 98144
Country: US
RegDate: 2005-09-29
Updated: 2009-06-02
Comment: For details of this service please see
Comment: http://ec2.amazonaws.com/
Ref: http://whois.arin.net/rest/org/AMAZO-4

OrgTechHandle: ANO24-ARIN
OrgTechName: Amazon EC2 Network Operations
OrgTechPhone: +1-206-266-4064
OrgTechEmail: aes-noc@amazon.com
OrgTechRef: http://whois.arin.net/rest/poc/ANO24-ARIN

OrgAbuseHandle: AEA8-ARIN
OrgAbuseName: Amazon EC2 Abuse
OrgAbusePhone: +1-206-266-4064
OrgAbuseEmail: ec2-abuse@amazon.com
OrgAbuseRef: http://whois.arin.net/rest/poc/AEA8-ARIN

DNS records
name class type data time to live
http://www.pageinsider.com IN CNAME pageinsider.com 300s (00:05:00)
pageinsider.com IN NS ns-312.awsdns-39.com 172800s (2.00:00:00)
pageinsider.com IN NS ns-629.awsdns-14.net 172800s (2.00:00:00)
pageinsider.com IN NS ns-1421.awsdns-49.org 172800s (2.00:00:00)
pageinsider.com IN NS ns-1679.awsdns-17.co.uk 172800s (2.00:00:00)
pageinsider.com IN SOA
server: ns-1421.awsdns-49.org
email: awsdns-hostmaster@amazon.com
serial: 1
refresh: 7200
retry: 900
expire: 1209600
minimum ttl: 86400
900s (00:15:00)
pageinsider.com IN A 23.21.64.216 300s (00:05:00)
pageinsider.com IN NS ns-312.awsdns-39.com 172800s (2.00:00:00)
pageinsider.com IN NS ns-629.awsdns-14.net 172800s (2.00:00:00)
pageinsider.com IN NS ns-1421.awsdns-49.org 172800s (2.00:00:00)
pageinsider.com IN NS ns-1679.awsdns-17.co.uk 172800s (2.00:00:00)
pageinsider.com IN SOA
server: ns-1421.awsdns-49.org
email: awsdns-hostmaster@amazon.com
serial: 1
refresh: 7200
retry: 900
expire: 1209600
minimum ttl: 86400
900s (00:15:00)
pageinsider.com IN A 23.21.64.216 300s (00:05:00)
74.103.21.23.in-addr.arpa IN PTR ec2-23-21-103-74.compute-1.amazonaws.com 300s (00:05:00)
103.21.23.in-addr.arpa IN NS pdns1.ultradns.net 900s (00:15:00)
103.21.23.in-addr.arpa IN NS pdns2.ultradns.net 900s (00:15:00)
103.21.23.in-addr.arpa IN NS pdns3.ultradns.org 900s (00:15:00)
103.21.23.in-addr.arpa IN NS pdns4.ultradns.org 900s (00:15:00)
103.21.23.in-addr.arpa IN NS pdns5.ultradns.info 900s (00:15:00)
103.21.23.in-addr.arpa IN NS pdns6.ultradns.co.uk 900s (00:15:00)
103.21.23.in-addr.arpa IN SOA
server: dns-external-master.amazon.com
email: root@amazon.com
serial: 5
refresh: 3600
retry: 900
expire: 604800
minimum ttl: 900
900s (00:15:00)
— end —

www.webutation.net

Address lookup
canonical name http://www.webutation.net

aliases
addresses 85.13.132.247
Domain Whois record

Queried whois.internic.net with “dom webutation.net

Domain Name: WEBUTATION.NET
Registrar: FASTDOMAIN, INC.
Whois Server: whois.fastdomain.com
Referral URL: http://www.fastdomain.com
Name Server: NS5.KASSERVER.COM
Name Server: NS6.KASSERVER.COM
Status: clientTransferProhibited
Updated Date: 25-aug-2011
Creation Date: 27-aug-2010
Expiration Date: 27-aug-2012

Last update of whois database: Thu, 28 Jun 2012 13:12:44 UTC
Queried whois.fastdomain.com with “webutation.net”…

=-=-=-=
Registrar: FastDomain Inc.
Provider Name….: BlueHost.Com
Provider Whois…: whois.bluehost.com
Provider Homepage: http://www.bluehost.com/

Domain Name: WEBUTATION.NET

Created on…………..: 2010-08-27 09:01:07 GMT
Expires on…………..: 2012-08-27 10:01:07 GMT
Last modified on……..: 2011-08-25 13:48:56 GMT

Registrant Info: (FAST-18446916)

Domain Privacy Service
1958 South 950 East
Provo, Utah –
United States
Phone: +1.8017659400
Fax..:
Email: whois@bluehost.com
Last modified: 2012-06-11 20:32:02 GMT

Administrative Info: (FAST-18446916)

Domain Privacy Service
1958 South 950 East
Provo, Utah –
United States
Phone: +1.8017659400
Fax..:
Email: whois@bluehost.com
Last modified: 2012-06-11 20:32:02 GMT

Technical Info: (FAST-18446916)

Domain Privacy Service
1958 South 950 East
Provo, Utah –
United States
Phone: +1.8017659400
Fax..:
Email: whois@bluehost.com
Last modified: 2012-06-11 20:32:02 GMT

Status: Locked

Domain servers in listed order:

NS5.KASSERVER.COM
NS6.KASSERVER.COM
=-=-=-=
Network Whois record
Queried whois.ripe.net with “-B 85.13.132.247″…
Information related to ‘85.13.128.0 – 85.13.159.255’

inetnum: 85.13.128.0 – 85.13.159.255
netname: NMM-NET-1
descr: Neue Medien Muennich GmbH
country: DE
remarks: ***********************************************
remarks: static ip network
remarks: For spam, abuse & security issues please contact abuse@kasserver.com
remarks: ***********************************************
org: ORG-NMMG1-RIPE
admin-c: RM1862-RIPE
tech-c: RM1862-RIPE
status: ASSIGNED PA
mnt-by: nmm-mnt
notify: hostmaster@kasserver.com
changed: wk@all-inkl.com 20110922
changed: wk@all-inkl.com 20120201
source: RIPE

organisation: ORG-NMMG1-RIPE
org-name: Neue Medien Muennich GmbH
org-type: LIR
address: Neue Medien Muennich GmbH
HAUPTSTRASSE 68
02742 FRIEDERSDORF
Germany
phone: +493587235310
fax-no: +493587235330
e-mail: wk@all-inkl.com
abuse-mailbox: abuse@all-inkl.com
admin-c: RM1862-RIPE
mnt-ref: RIPE-NCC-HM-MNT
mnt-ref: nmm-mnt
mnt-by: RIPE-NCC-HM-MNT

person: Rene Muennich
address: Neue Medien Muennich GmbH
address: Hauptstrasse 68
address: D-02742 Friedersdorf
phone: +49 35872 353 10
fax-no: +49 35872 353 30
e-mail: ip@all-inkl.com
abuse-mailbox: ip@all-inkl.com
nic-hdl: RM1862-RIPE
mnt-by: LNC-MNT
changed: registry@undeliverable.lambdanet.net 20050523
source: RIPE

Information related to ‘85.13.128.0/19AS34788’

route: 85.13.128.0/19
descr: Neue Medien Muennich
origin: AS34788
mnt-by: nmm-mnt
changed: hostmaster@kasserver.com 20060426
source: RIPE

% This query was served by the RIPE Database Query Service version 1.15 (WHOIS3)

DNS records
name class type data time to live
http://www.webutation.net IN A 85.13.132.247 7200s (02:00:00)
webutation.net IN SOA
server: ns5.kasserver.com
email: root@kasserver.com
serial: 2012060716
refresh: 28800
retry: 7200
expire: 1209600
minimum ttl: 7200
7200s (02:00:00)
webutation.net IN A 85.13.132.247 7200s (02:00:00)
webutation.net IN MX
preference: 10
exchange: mail.webutation.net
7200s (02:00:00)
webutation.net IN NS ns5.kasserver.com 7200s (02:00:00)
webutation.net IN NS ns6.kasserver.com 7200s (02:00:00)
webutation.net IN TXT kasserver.com 7200s (02:00:00)
247.132.13.85.in-addr.arpa IN PTR dd10032.kasserver.com 3429s (00:57:09)
85.in-addr.arpa IN SOA
server: pri.authdns.ripe.net
email: dns@ripe.net
serial: 1340817482
refresh: 3600
retry: 600
expire: 864000
minimum ttl: 7200
3600s (01:00:00)
85.in-addr.arpa IN NS tinnie.arin.net 172800s (2.00:00:00)
85.in-addr.arpa IN NS pri.authdns.ripe.net 172800s (2.00:00:00)
85.in-addr.arpa IN NS sec3.apnic.net 172800s (2.00:00:00)
85.in-addr.arpa IN NS sns-pb.isc.org 172800s (2.00:00:00)
85.in-addr.arpa IN NS ns3.nic.fr 172800s (2.00:00:00)
85.in-addr.arpa IN NS sec1.apnic.net 172800s (2.00:00:00)
85.in-addr.arpa IN NSEC
next domain name: 0.85.in-addr.arpa
record types: NS SOA RRSIG NSEC DNSKEY
7200s (02:00:00)
85.in-addr.arpa IN DNSKEY
flags: ZoneKey (256)
protocol: 3
algorithm: RSA/SHA-1 (5)
public key:
(1056 bits)

3600s (01:00:00)
85.in-addr.arpa IN DNSKEY
flags: SecureEntryPoint, ZoneKey (257)
protocol: 3
algorithm: RSA/SHA-1 (5)
public key:
(2080 bits)

3600s (01:00:00)
85.in-addr.arpa IN DNSKEY
flags: SecureEntryPoint, ZoneKey (257)
protocol: 3
algorithm: RSA/SHA-1 (5)
public key:
(2080 bits)

3600s (01:00:00)
85.in-addr.arpa IN DNSKEY
flags: ZoneKey (256)
protocol: 3
algorithm: RSA/SHA-1 (5)
public key:
(1056 bits)

3600s (01:00:00)
85.in-addr.arpa IN RRSIG
type covered: NS (2)
algorithm: RSA/SHA-1 (5)
labels: 3
original ttl: 172800 (2.00:00:00)
signature expiration: 2012-07-28 10:02:05Z
signature inception: 2012-06-28 09:02:05Z
key tag: 52063
signer’s name: 85.in-addr.arpa
signature:
(1024 bits)

172800s (2.00:00:00)
85.in-addr.arpa IN RRSIG
type covered: SOA (6)
algorithm: RSA/SHA-1 (5)
labels: 3
original ttl: 3600 (01:00:00)
signature expiration: 2012-07-28 10:02:05Z
signature inception: 2012-06-28 09:02:05Z
key tag: 52063
signer’s name: 85.in-addr.arpa
signature:
(1024 bits)

3600s (01:00:00)
85.in-addr.arpa IN RRSIG
type covered: NSEC (47)
algorithm: RSA/SHA-1 (5)
labels: 3
original ttl: 7200 (02:00:00)
signature expiration: 2012-07-28 10:02:05Z
signature inception: 2012-06-28 09:02:05Z
key tag: 52063
signer’s name: 85.in-addr.arpa signature:(1024 bits)

7200s (02:00:00)
85.in-addr.arpa IN RRSIG
type covered: DNSKEY (48)
algorithm: RSA/SHA-1 (5)
labels: 3
original ttl: 3600 (01:00:00)
signature expiration: 2012-07-28 10:02:05Z
signature inception: 2012-06-28 09:02:05Z
key tag: 5504
signer’s name: 85.in-addr.arpa
signature:
(2048 bits)
3600s (01:00:00)
— end —

VA gets GIBill.com domain, Oregon and other states get cash in settlement

If you’re a veteran who has surfed the Web looking for benefits information, you may have alighted on GIBill.com. Until now, that domain and others have been operated by a marketing company called QuinStreet, which bills itself as “the leader in vertical media and marketing online.”

But under a settlement announced Wednesday, QuinStreet will turn GIBill.com over to the Department of Veterans Affairs and will pay $2.5 million to cover the costs of the 20 states who have been investigating the company’s practices. Oregon’s share will be $225,000, the Oregon Department of Justice announced.

The states accused QuinStreet of misleading veterans by guiding them to apply their GI Bill benefits only to for-profit institutions and by implying that it was an official government website. QuinStreet denied that it misled veterans, but said it agreed to terms in order to provide clarity.

The GI Bill assists veterans who attend schools, including public universities like Portland State University and the University of Oregon.

http://blog.oregonlive.com/oregonatwar/2012/06/va_gets_gibillcom_domain_orego.html